Advancing a class on top of statins
World Class Leadership
Management Team
Steve Gullans Chief Executive Officer
Mina Sooch


Dr. Gullans has broad experience across the life sciences industry including being a board director at Gemphire since 2016, prior to joining full-time 2018. Previously Dr. Gullans was Managing Director at Excel Venture Management, a Boston-based life sciences venture capital firm which he cofounded in 2008. At Excel he spearheaded many successful investments in a variety of therapeutics and diagnostics companies, including Cleveland HeartLab. Prior to Excel, Dr. Gullans was co-founder and CEO of RxGen, Inc. and Chief Scientific Officer at U.S. Genomics. Currently Dr. Gullans is a director and co-founder of Orionis Biosciences LLC, a biotech therapeutics company and a director of N-of-One Inc., an oncology diagnostics entity. He advises on innovation at the Cleveland Clinic and Partners HealthCare.

For nearly 20 years, Dr. Gullans was a faculty member at Harvard Medical School and Brigham and Women’s Hospital where he published more 130 research papers in many fields. Dr. Gullans is passionate about innovation and co-authored two books with Juan Enriquez, including “Evolving Ourselves,” a book that provides a sweeping tour of how humans are changing the course of evolution. Dr. Gullans has spoken globally including at TEDMED and TEDx. He received his Ph.D. from Duke University, post-doctoral training at Yale University, and his B.S. from Union College. He is an elected Fellow of the American Heart Association as well as the American Association for the Advancement of Science.

Charles Bisgaier Chief Scientific Officer and Co-Founder
Charles Bisgaier


Dr. Bisgaier serves as our Chairman and Chief Scientific Officer. From 1990 to 1998, Dr. Bisgaier was an Associate Research Fellow in the Department of Vascular and Cardiac Disease at Warner-Lambert/Parke-Davis. There he participated in the discovery and/or development of gemfibrozil (LOPID®), atorvastatin (LIPITOR®) and gemcabene (AKA CI-1027 and PD 72953). Subsequently, Dr. Bisgaier co-founded the first Esperion Therapeutics (1998- 2004), which was then acquired by Pfizer. At Pfizer he then served as the Senior Director of Pharmacology at the Esperion Division of Pfizer Global Research and Development. Notably, he was a major influence in the discovery, research and/or development of many small molecules with potential utility for metabolic syndrome including ETC-1002 (AKA ESP 55016) which was licensed by the new Esperion (NASDAQ: ESPR) from Pfizer, as well as HDL-therapy product candidates, such as ApoA-I Milano (ETC-216) which was also licensed by The Medicines Company (NASDAQ: MDCO) from Pfizer. After Pfizer, he served as a Company Director, Board Member and President of Pipex Pharmaceuticals (2006-2008, currently known as Synthetic Biologics, NYSE: SYN), a specialty pharmaceutical company focused on developing fibrotic and neurological disease therapies, that included a treatment for Relapsing Remitting Multiple Sclerosis. Both Pipex Pharmaceuticals and the first Esperion Therapeutics became public companies through a reverse-merger and an initial public offering (IPO), respectively during Dr. Bisgaier's tenure. He is also a co-founder of Michigan Life Therapeutics (predecessor to Gemphire) and Michigan Life Ventures. In addition, he is currently a Board member at Hygieia, Inc., a company that has developed a novel handheld medical device to assist diabetics to determine appropriate dosage when self-administering insulin, and a Board member at BioSavita Inc., a company that has developed a novel platform technology for protein expression in yeast. He also has served as a Board member (2009-2014) and President and CEO (2010-2011) of ProNAi Therapeutics (NASDAQ: DNAI). Currently, Dr. Bisgaier is also an Adjunct Associate Professor of Pharmacology at the University of Michigan. He received a B.A. in Biology from the State University College at Oneonta, NY (1974), and a M.S.(1977) and Ph.D. (1981) in biochemistry from George Washington University, Washington, D.C. After receiving his doctorate, he studied lipoprotein metabolism within the Specialized Center of Research (SCOR) for atherosclerosis at Columbia University College of Physicians and Surgeons, NY.

Seth Reno Chief Commercial Officer
David Lowenschuss


Mr. Reno serves as our Chief Commercial Officer and has over 25 years of experience in the Bio-Pharmaceutical industry. He has extensive experience in building commercial capabilities to successfully commercialize both small and large molecules across a range of therapeutic areas including the cardiovascular market. Prior to joining Gemphire, he spent five years at Medimmune building commercial teams and capabilities that focused on launching complex biologics such as Mylept and Lynparza with orphan designation status into rare disease markets. As Medimmune’s Head of Commercial Operations he was responsible for leading core business functions across: Sales Operations, Marketing Operations, Market Research, Fleet Services, Sales Training, Commercial Insight, Advanced Analytics and Forecasting. Mr. Reno spent ten years at AstraZenca across a number of roles in Sales, Commercial Operations, Managed Markets and Brand Team. He led the Commercial Insight’s team for the dyslipidemia franchise, most notably the successful launch of Crestor’s atherosclerosis indication. He also led the insight work for several mixed dyslipidemia fixed dose combinations in development with industry partners. Prior to Joining AstraZeneca in 2001, Mr. Reno Spent eleven years at Wyeth in commercial operations and sales account management successfully building B2B relationships across Federal, Trade, Military and Commercial accounts. Mr. Reno holds a B.S. in Human Resources from University of Delaware and a MBA from Strayer University.